<DOC>
	<DOCNO>NCT01295762</DOCNO>
	<brief_summary>Apart brain tumor , Neuroblastoma common solid tumor childhood . About 50 % case present diagnosis factor bad prognosis . During last two decade , despite increase therapeutic intensity induction consolidation high-risk neuroblastoma , 5 year overall survival high risk neuroblastoma remain 30 40 % depend study . Besides strategy high-dose chemotherapy follow autologous transplantation hematopoietic stem cell , differentiate molecule ( retinoids ) , immunotherapy become one leading anti-neuroblastoma targeted therapy . No therapeutic strategy molecule obtain gain survival ever . Studying immune system child neuroblastoma diagnosis treatment help u determine test active passive immunotherapy strategy . Moreover , study would allow u specify cause tumor immune tolerance neuroblastoma , data comparison adult tumor . This multicentric , pilot , prospective , open , study require unusual diagnostic intervention . This study transversal ( neuroblastoma stage include ) order determine comparative criterion low high risk neuroblastoma . It also longitudinal ( diagnosis post-treatment follow-up ) order specify evolutionary aspect immunity radio-chemotherapy retinoic acid therapy . Immunological analysis do blood , bone marrow tumor sample , diagnosis , treatment child diagnose neuroblastoma ( 3 time point ) . These type sample routinely do conventional neuroblastoma treatment .</brief_summary>
	<brief_title>Immunomonitoring Children With Neuroblastoma</brief_title>
	<detailed_description>The main objective study description immune effector blood , marrow tumor diagnosis . During 3 year , trial include 30 child pediatric oncology unit Lyon , Saint-Etienne , Grenoble Clermont-Ferrand . The study duration 5 year . Children follow-up schedule least 2 year order determine predictive factor therapeutic efficiency survival . Multi-parametric marker set ( 6-8 marker per sample ) already develop validate analyze absolute amount proportion immune subpopulation ( B , TCD4+ , TCD8+ , Treg , NK , DC ) activation status ( PD1 , ICOS , CD39 , CD73 , CD62L , CCR7 , CD45RO , CD45RA , CD86 , Ox40 , CD137 , CTLA4 ) small volume . At least , analysis perform blood marrow sample . If amount blood mononuclear cell harvest allows , functional analysis undertake ( intracytoplasmic cytokine response activation T , DC , NK ; protocol set ) . Immunostainings perform tumor sample diagnosis resection primary tumor , order determine expression evolution several immunomodulatory molecule neuroblastoma cell ( HLA class I &amp; II , HLA-G , IDO , IL10 , … ) . , also determine immune infiltrate within tumor microenvironment ( lymphocytes Treg , cellules dendritiques , MDSC , … ) . The technique use mostly classical immunology ( IHC , IF , FACS ) , already set-up INSERM team adult tumor . Children 's plasma screen specific anti-tumor immunoglobulin diagnosis key treatment time point . In meanwhile , level circulate cytokine concentration evaluate Luminex , especially know inhibitory effect immune effector : IL-4 , IL-5 , IL-6 , IL-10 , TGF-beta , HLA-Gs , TNF-alpha , IFN-gama , IL-2 , IL-12 , IL-27 , IL-17 CD40L ( already place ) .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Age &lt; = 21 year Patient neuroblastoma stage , first line relapse , suspicion neuroblastoma Covered medical insurance Written , sign inform consent ( patient , parent minor child ) Patients receive corticosteroid within 15 day prior sample Patients receive immunosuppressive therapy Chemotherapy sampling begin Neuroblastoma genetic syndrome predisposing Deterioration clinical status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Children</keyword>
	<keyword>Cancer</keyword>
	<keyword>Immunomonitoring</keyword>
	<keyword>Prognostic/Predictive Factors</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>